Pharmacological Action Clinical Trial
— BARI-COVIDOfficial title:
Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study
There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. Since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.The evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | July 30, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - All consecutive patients with mild to moderate COVID-19 infection - Age >18 years, - Clinical diagnosis of COVID19 infection - Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia. - All patients should be willing and able to provide written informed consent prior to performing study procedures. Exclusion Criteria: - Age less than 18 - History of thrombophlebitis. - Patient with latent tuberculosis infection (Quantiferon test). - Pregnancy and lactation. |
Country | Name | City | State |
---|---|---|---|
Italy | Fabrizio Cantini | Prato | Tuscany |
Lead Sponsor | Collaborator |
---|---|
Hospital of Prato |
Italy,
Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087. — View Citation
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282. [Epub ahead of print] — View Citation
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review. — View Citation
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:. — View Citation
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4. — View Citation
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. — View Citation
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. — View Citation
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls. | The percentage of ICU admission in patients and controls will be compared for statistical difference | 2 weeks | |
Secondary | The percentage of patients achieving the remission; CRP, IL-6 and TNFa values at baseline and during the treatment course; the number of AEs. | CRP values will be evaluated for prediction of disease worsening. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06040853 -
Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia?
|
Phase 4 | |
Not yet recruiting |
NCT05553496 -
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT05534802 -
Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass
|
N/A | |
Recruiting |
NCT04190537 -
PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
|
||
Completed |
NCT03119454 -
"Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice
|
N/A | |
Completed |
NCT03522532 -
Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid
|
N/A | |
Unknown status |
NCT01614353 -
Medication-taking Preferences & Practices of Patients With Chronic Conditions
|
N/A | |
Completed |
NCT03714360 -
The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery.
|
Phase 4 | |
Recruiting |
NCT03352622 -
Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis
|
N/A | |
Recruiting |
NCT06288841 -
Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study
|
N/A | |
Completed |
NCT03359590 -
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
|
Phase 2 | |
Completed |
NCT05591105 -
Morphine Consumption in the Obese Patients
|
||
Not yet recruiting |
NCT03904303 -
Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep
|
Phase 1 | |
Not yet recruiting |
NCT05453045 -
Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva
|
N/A | |
Completed |
NCT05428683 -
Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery
|
N/A | |
Enrolling by invitation |
NCT02985281 -
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06222710 -
Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy
|
N/A | |
Not yet recruiting |
NCT03953287 -
Pharmacokinetic Study of Paracetamol.
|
Phase 1 | |
Recruiting |
NCT03622047 -
Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil
|
N/A | |
Active, not recruiting |
NCT06324370 -
Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO)
|
N/A |